Pharma Capital

Drug developer Ergomed set to kick off phase II trial on treatment for surgical bleeding

Sales of PeproStat can be as high as US$500mln believes Ergomed
shutterstock_212432119_58cf855ac517b.jpg
The treatment is designed to staunch heavy bleeding during surgery

Ergomed Plc (LON:ERGO) has begun recruiting for a phase IIb proof-of-concept study on Peprostat to treat a surgical complication called intraoperative bleeding.

A total of 120 people will be enrolled to the trial at 30 centres across in seven European countries. 

Researchers want to assess PeproStat’s ability to control bleeding during surgery in four different procedures - liver, soft tissue, vascular and spinal.

Top line results are expected in the first quarter of next year.

WATCH: Ergomed's Andrew Mackie and Haemostatix's Ben Nichols talk to Proactive's Stocktube about the 'milestone' trial

Ergomed said PeproStat could, potentially be a “disruptive” product in the US$2.5bn market for surgical haemostats. 

Current treatments are limited by a range of issues, including slow onset of action, lack of effect on stronger bleeds and long preparation time.

The Ergomed-developed solution eliminates the risk of exposure to blood derived materials, is more stable allowing the formulation of ready-to-use preparations and has a fast mode of action.

“With these advantages we expect the product to gain significant market share,” the AIM-listed drug developer said.

Chief executive, Dr Miroslav Reljanovic, called the phase II study a “major milestone” following Ergomed’s acquisition of Haemostatix last May in a deal worth an initial £8mln.

"We believe that we have a good chance of obtaining successful results, and with that a compelling data package to advance the product into late stage development and commercial collaboration," said Reljanovic.

Ergomed sees sales potential of up to US$500mln and even if this diluted by partner coming on board at some time, it would be still be transformational for the company added Andrew Mackie, chief business officer.

Shares rose 4% to 190p.

 

--- Updates with video, line and share price ---

Ian_55ae0ddd437b7.jpg
Why Invest In Ergomed Plc? Read More Here

Register here to be notified of future ERGO Company articles
View full ERGO profile

Ergomed Plc Timeline

Newswire

Boardroom reshuffle at Ergomed

View All

Related Articles

picture of drug research
“The positive results from this feasibility award may lead to other opportunities to secure additional funding awards to advance the programme further," Dr John Reader, Sareum's chief scientific officer said.
Cattle-herd-(Resized).jpg
If UniBio’s plans come to fruition it won’t be too long before the company orchestrates a major adjustment to the food-chain.

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.